Ken Griffin Praxis Precision Medicines, Inc. Transaction History

Citadel Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.87 - $1.71 $35,382 - $69,543	-40,669 Reduced 6.17%	618,540 $1.06 Million
Q2 2023 Aug 14, 2023	BUY	$0.83 - $1.18 $29,400 - $41,797	35,422 Added 5.68%	659,209 $758,000
Q1 2023 May 15, 2023	SELL	$0.8 - $4.98 $105,234 - $655,084	-131,543 Reduced 17.42%	623,787 $505,000
Q4 2022 Feb 14, 2023	SELL	$1.88 - $36.45 $612,445 - $11.9 Million	-325,769 Reduced 30.13%	755,330 $1.8 Million
Q3 2022 Nov 14, 2022	SELL	$2.5 - $37.95 $896,487 - $13.6 Million	-358,595 Reduced 24.91%	1,081,099 $2.45 Million
Q2 2022 Aug 15, 2022	SELL	$1.75 - $11.34 $193,571 - $1.25 Million	-110,612 Reduced 7.13%	1,439,694 $3.53 Million
Q1 2022 May 16, 2022	SELL	$10.21 - $20.29 $747,545 - $1.49 Million	-73,217 Reduced 4.51%	1,550,306 $15.8 Million
Q4 2021 Feb 14, 2022	SELL	$16.76 - $22.99 $254,869 - $349,608	-15,207 Reduced 0.93%	1,623,523 $32 Million
Q3 2021 Nov 15, 2021	SELL	$13.15 - $22.56 $2.9 Million - $4.97 Million	-220,183 Reduced 11.84%	1,638,730 $30.3 Million
Q2 2021 Aug 16, 2021	BUY	$18.28 - $33.05 $4.68 Million - $8.46 Million	256,033 Added 15.97%	1,858,913 $34 Million
Q1 2021 May 17, 2021	BUY	$29.34 - $60.2 $212,245 - $435,486	7,234 Added 0.45%	1,602,880 $52.5 Million
Q4 2020 Feb 16, 2021	BUY	$27.25 - $55.82 $43.5 Million - $89.1 Million	1,595,646 New	1,595,646 $87.8 Million

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.52B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.